Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2025-10-20 | Reverse | 1:20 |
Senseonics Holdings, Inc. develops and markets implantable CGM systems like Eversense for diabetes management worldwide, offering real-time glucose monitoring via a sensor, smart transmitter, and app.

Eversense 365 is an implantable CGM system with a year-long sensor, a removable transmitter, and a mobile app, offering accurate glucose monitoring and reducing the need for frequent sensor replacements for people with diabetes.
| Map | REGION | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | UNITED STATES | $6.42M | $12.05M ▲ | $9.33M ▼ | $12.57M ▲ |
![]() | NonUS | $1.67M | $5.67M ▲ | $2.38M ▼ | $1.91M ▼ |
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
ACRS | $6.17 | COMPARE |
CAPR | $9.40 | COMPARE |
CERS | $2.59 | COMPARE |
NPCE | $14.90 | COMPARE |
SGHT | $8.35 | COMPARE |
MASS | $10.05 | COMPARE |
QTRX | $2.69 | COMPARE |
CVRX | $3.05 | COMPARE |